SRRA News and Press, Sierra Oncology Inc. From 01/19/22

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the publication of a review article in the Journal of Hematology & Oncology that outlines the potential ability of momelotini...

—Company now anticipates MOMENTUM topline data readout by the end of January 2022— Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced it has shortened the tim...

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 2022 HC Wainwright BioConnect Conference being held virtually from January 10-13, 2022. Stephen D...

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced data from new retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate baseline ferritin differentially pred...

—Topline data expected by February 2022— —Prithviraj Bose, MD, to join Sierra Oncology Leadership to discuss importance of treating anemia in myelofibrosis patients— Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical comp...

Sierra Oncology (NASDAQ:SRRA) granted stock options to six new employees as approved by the Compensation Committee of the company's board. In total, the employees received options to purchase 39K shares of Sierra's common stock; options have an exercise price of $23.28/share. The options...

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in the 2021 Jefferies London Healthcare Conference. Stephen Dilly, MBBS, PhD, President a...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., ...

– MOMENTUM study on track for topline data read-out by February 2022 – – Global in-licensing deal expands myelofibrosis pipeline and provides options for combination studies in other hematologic malignancies and solid tumors – Sierra Oncol...

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced new retrospective analyses of the momelotinib Phase 3 SIMPLIFY studies will be presented at the 63 rd American Soc...